Investment Thesis
China Pharma faces a critical liquidity crisis with current ratio of 0.28x and only $168.5K cash against $114.6K annual free cash burn, implying ~18-month runway. Persistent operating losses at -113.6% margin with declining revenue and negative operating cash flow indicate an unsustainable business model at imminent risk of insolvency.
Strengths
- Gross margin of 29% demonstrates core products retain some commercial viability at product level
- Stockholders equity of $37M provides accounting buffer above total liabilities of $8.1M
- Net loss improved 32.7% year-over-year suggesting partial operational improvement trajectory
Risks
- Critical liquidity crisis: current ratio 0.28x and quick ratio 0.07x with only $168.5K cash position company at immediate solvency risk
- Negative free cash flow of -$114.6K annually against minimal cash creates ~18-month runway before potential insolvency without capital infusion
- Persistent deep operating losses at -113.6% margin with declining revenue (-8.5% YoY) and negative operating cash flow indicate broken business economics
- Pharmaceutical sector capital requirements incompatible with company's inability to achieve profitability or positive cash generation
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway - absolute critical indicator of survival timeline
- Revenue stabilization and positive year-over-year growth - prerequisite for any path to viability
- Operating margin improvement trajectory toward breakeven and positive operating cash flow
Financial Metrics
Revenue
983.5K
Net Income
-1.1M
EPS (Diluted)
$-0.04
Free Cash Flow
-114.6K
Total Assets
45.1M
Cash
168.5K
Profitability Ratios
Gross Margin
29.0%
Operating Margin
-113.6%
Net Margin
-116.2%
ROE
-3.1%
ROA
-2.5%
FCF Margin
-11.7%
Balance Sheet & Liquidity
Current Ratio
0.28x
Quick Ratio
0.07x
Debt/Equity
0.12x
Debt/Assets
18.0%
Interest Coverage
-122.98x
Long-term Debt
4.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T08:03:31.696316 |
Data as of: 2026-03-31 |
Powered by Claude AI